News | March 02, 2026
Moderna wins EU backing for world’s first combined flu-COVID shot
The decision marks a pivotal moment for the Massachusetts-based biotech giant
The decision marks a pivotal moment for the Massachusetts-based biotech giant
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
The new patents cover critical advancements in cochlear implant technology
The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner
The order will cover the manufacturing of bulk vaccine in 2026
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
Subscribe To Our Newsletter & Stay Updated
